Record #:

17044

Author(s):

Norris, Jeannie Faris

Abstract:

Hemocellular Therapeutics, expected to produce the first platelet-based therapeutic available to doctors for the immediate treatment of active bleeding, has established an exclusive licensing agreement with UNC-Chapel Hill and East Carolina University. Key technology developed by researchers at the two universities was central to the development by Hemocellular of a plan to create lyophilized, or \"freeze-dried\" human platelets. The licensing agreement provides for both universities to receive equity in Hemocellular and to share in royalties on the sale of the products.

Source:

Metro Magazine (NoCar F 264 R1 M48), Vol. 4 Issue 5, June 2003, p14

Subject(s):

University of North Carolina at Chapel Hill